• +1-646-491-9876
    • +91-20-67278686

    Search

    Angiopoietin 1 Receptor-Pipeline Review H2 2017

    Angiopoietin 1 Receptor-Pipeline Review H2 2017

    • Report Code ID: RW0001881481
    • Category Life Sciences
    • No. of Pages 94
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1)-Pipeline Review H2 2017

    Summary

    Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1)-Angiopoietin-1 receptor or CD202B is a protein encoded by the TEK gene.It regulates angiogenesis endothelial cell survival proliferation migration adhesion and cell spreading reorganization of the actin cytoskeleton. It also maintains of vascular quiescence. It has anti-inflammatory effects by preventing the leakage of proinflammatory plasma proteins and leukocytes from blood vessels. It is required for normal angiogenesis and heart development during embryogenesis. It is required for post-natal hematopoiesis.

    Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies.The molecules developed by companies in Pre-Registration Phase III Phase I and Preclinical stages are 1 1 2 and 4 respectively. Report covers products from therapy areas Oncology Metabolic Disorders Ophthalmology Cardiovascular and Male Health which include indications Glioblastoma Multiforme (GBM) Pancreatic Cancer Solid Tumor Bile Duct Cancer (Cholangiocarcinoma) Breast Cancer Colorectal Cancer Epithelial Ovarian Cancer Fallopian Tube Cancer Hepatocellular Carcinoma Metastatic Colorectal Cancer Peritoneal Cancer Relapsed Acute Myeloid Leukemia Soft Tissue Sarcoma Acute Myelocytic Leukemia (AML Acute Myeloblastic Leukemia) Adenoid Cystic Carcinoma (ACC) Adrenocortical Carcinoma (Adrenal Cortex Cancer) Bladder Cancer Chronic Myelocytic Leukemia (CML Chronic Myeloid Leukemia) Diabetic Foot Ulcers Diabetic Macular Edema Endometrial Cancer Erectile Dysfunction Gastric Cancer Gastrointestinal Stromal Tumor (GIST) Liver Cancer Lung Cancer Medullary Thyroid Cancer Melanoma Metastatic Brain Tumor Metastatic Breast Cancer Metastatic Renal Cell Carcinoma Myelodysplastic Syndrome Myelofibrosis Myocardial Infarction Neuroendocrine Tumors Non-Rhabdomyosarcoma Non-Small Cell Lung Cancer Ocular Melanoma Open-Angle Glaucoma Ovarian Cancer Pheochromocytoma Refractory Acute Myeloid Leukemia Refractory Multiple Myeloma Relapsed Multiple Myeloma Renal Cell Carcinoma Rhabdomyosarcoma Skin Cancer Transitional Cell Cancer (Urothelial Cell Cancer) Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Ureter Cancer Urethral Cancer Wet (Neovascular / Exudative) Macular Degeneration and Wilms' Tumor (Nephroblastoma) .

    The latest report Angiopoietin 1 Receptor-Pipeline Review H2 2017 outlays comprehensive information on the Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) targeted therapeutics complete with analysis by indications stage of development mechanism of action (MoA) route of administration (RoA) and molecule type. It also reviews key players involved in Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects.

    The report is built using data and information sourced from proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1)
    - The report reviews Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes product description descriptive MoA R&D brief licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA) route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information analysis and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1)-Overview
    Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1)-Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1)-Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1)-Companies Involved in Therapeutics Development
    Aerpio Therapeutics Inc
    Bayer AG
    Deciphera Pharmaceuticals LLC
    Exelixis Inc
    PharmAbcine Inc
    Q BioMed Inc
    Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1)-Drug Profiles
    altiratinib-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AP-185-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ARP-1536-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    cabozantinib s-malate-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MAN-01-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PMC-001-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    rebastinib tosylate-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    regorafenib-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1)-Dormant Products
    Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1)-Discontinued Products
    Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1)-Product Development Milestones
    Featured News & Press Releases
    Jun 28 2017 EMA Recommends Extensions of Therapeutic Indications for Regorafenib
    Jun 26 2017 Bayer Receives Approval for Stivarga in Japan for Second-Line Treatment of Hepatocellular Carcinoma
    Jun 23 2017 Bayer Receives Positive CHMP Opinion for regorafenib for the Second-Line Systemic Treatment of Liver Cancer
    Jun 19 2017 Ipsen and its Partner Exelixis Announce Independent Radiology Committee Review Confirms Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma
    Jun 12 2017 Exelixis Announces Initiation of Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors
    Jun 12 2017 Scotland first in UK to make Cabometyx (cabozantinib) routinely available for individuals living with advanced kidney cancer
    Jun 01 2017 Ipsen To Present New Data of Cabometyx at ASCO
    Apr 27 2017 FDA expands approved use of Stivarga to treat liver cancer
    Apr 07 2017 Allegheny Health Network Clinical Trial Examines Kinase Inhibitor Regorafenib as Maintenance Therapy for Colon Cancer
    Mar 06 2017 Exelixis' Cabozantinib Granted Orphan Drug Designation for the Treatment of Hepatocellular Carcinoma
    Feb 17 2017 Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
    Feb 02 2017 Q BioMed Announces Mannin Research Accepted Into Johnson & Johnson Innovation JLABS@ Toronto
    Jan 20 2017 Regorafenib from Bayer Granted Priority Review in Japan for the Second-Line Treatment of Liver Cancer
    Jan 18 2017 Bayer to Reveal Latest Data on Regorafenib at ASCO GI 2017
    Jan 18 2017 Mount Sinai researchers involved in successful phase 3 trial of drug for liver cancer
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development H2 2017
    Number of Products under Development by Therapy Areas H2 2017
    Number of Products under Development by Indications H2 2017
    Number of Products under Development by Indications H2 2017 (Contd..1) H2 2017
    Number of Products under Development by Indications H2 2017 (Contd..2) H2 2017
    Number of Products under Development by Companies H2 2017
    Products under Development by Companies H2 2017
    Products under Development by Companies H2 2017 (Contd..1) H2 2017
    Products under Development by Companies H2 2017 (Contd..2) H2 2017
    Products under Development by Companies H2 2017 (Contd..3) H2 2017
    Number of Products by Stage and Mechanism of Actions H2 2017
    Number of Products by Stage and Route of Administration H2 2017
    Number of Products by Stage and Molecule Type H2 2017
    Pipeline by Aerpio Therapeutics Inc H2 2017
    Pipeline by Bayer AG H2 2017
    Pipeline by Deciphera Pharmaceuticals LLC H2 2017
    Pipeline by Exelixis Inc H2 2017
    Pipeline by PharmAbcine Inc H2 2017
    Pipeline by Q BioMed Inc H2 2017
    Dormant Products H2 2017
    Dormant Products H2 2017 (Contd..1) H2 2017
    Discontinued Products H2 2017

    List of Figures

    Number of Products under Development by Stage of Development H2 2017
    Number of Products under Development by Therapy Areas H2 2017
    Number of Products under Development by Top 10 Indications H2 2017
    Number of Products by Mechanism of Actions H2 2017
    Number of Products by Stage and Mechanism of Actions H2 2017
    Number of Products by Routes of Administration H2 2017
    Number of Products by Stage and Routes of Administration H2 2017
    Number of Products by Molecule Types H2 2017
    Number of Products by Stage and Molecule Types H2 2017
    Aerpio Therapeutics Inc
    Bayer AG
    Deciphera Pharmaceuticals LLC
    Exelixis Inc
    PharmAbcine Inc
    Q BioMed Inc

    Request for Sample

    Report Url https://www.reportsweb.com//angiopoietin-1-receptor-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//angiopoietin-1-receptor-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//angiopoietin-1-receptor-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments